Expression of ER, PR, C-erbB-2 and Ki-67 in Endometrial Carcinoma and their Relationships with the Clinicopathological Features

Yu, Cuige; Xiangyang, Jiang; Li, Bin; Gan, Lu; Huang, Jianfeng

doi:10.7314/apjcp.2015.16.15.6789

Cited by 24 publications

(27 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[26] However, in present study only 25% cases of carcinoma (5 out of 20) showed >35% expression of Ki67. Expression of Ki67 was positive in 64.1% and 41.5% cases of endometrial carcinoma in the study done by Cui-Ge Yu et al [27] and Suthipintawong C et al [23] However the small sample size was one of the major limitation of the present study. Since the study was conducted at a private tertiary care institution and a convenient sample was taken through complete enumeration process (during the time frame of study), the findings are subjected to selection bias.…”

Section: Discussionmentioning

confidence: 55%

“…In our study 100% of the cases of endometrial carcinoma showed positive expression of ER. However studies by Suthipintawong et al; [23] Suamchock et al; [24] Markova et al; [25] Sidonia et al; [26] Yu CG et al; [27] Pasam et al; [28] Musfera et al 29] ER expression was present in 76%, 59.3%, 79.3%,86.3%,44.7%, 68% and 60.7% of the cases respectively.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Histopathological and Immunohistochemical Study of Endometrial Lesions Obtained from D&C and Hysterectomy Specimens at a Tertiary Care Hospital

Bhattacharya

Jha²,

Agarwal³

et al. 2018

APALM

View full text Add to dashboard Cite

Background: Endometrial lesions are represented by a set of diversified disorders which has challenged clinicians for a long time. Due to its chances of progressing to malignant states, the condition needs prompt and focussed study, keeping clinical context in view. Methods: This 12-month (June 2016-May 2017) cross-sectional studyinvolved 100 specimens from dilatation and curettage (D & C) and hysterectomy specimens from female patientsaged ≥ 18 years who presented with complain of pelvic pain, abnormal uterine bleeding, dysmenorrhoea, pelvic mass and infertility. For all the specimens received,histopathological and immunohistochemical assessment was done. Results: Out of 100 cases of abnormal uterine bleeding 44 females showed physiological changes, 25 females showed benign lesions and 20 females had malignant lesions of endometrium. Out of 20 cases of endometrial carcinoma 50 % were well differentiated and 25% were moderately differentiated and 25% were poorly differentiated. Expression of Ki-67 was >35% in poorly differentiated carcinoma. Well differentiated carcinoma showed 80-85% positivity of ER, moderately differentiated showed 30-35% positivity and poorly differentiated carcinoma showed 6-12%. The association between benign and malignant endometrial lesion was found to be statistically significant with age-group, history of contraceptive use and chronic illnesses (p<0.05). Conclusion: Endometrial biopsy is one of the prompt tools in diagnosis and assessment of the benign and malignant diseases of endometrium. Immunohistochemical markers like ER (hormonal receptor) and Ki-67 (proliferative marker) play a major role in diagnosis, prognostication and therapeutic management of malignant cases.

show abstract

Section: Discussionmentioning

confidence: 55%

Section: Discussionmentioning

confidence: 99%

Histopathological and Immunohistochemical Study of Endometrial Lesions Obtained from D&C and Hysterectomy Specimens at a Tertiary Care Hospital

Bhattacharya

Jha²,

Agarwal³

et al. 2018

APALM

View full text Add to dashboard Cite

show abstract

“…Despite this, there was a strong interrelationship among the tumor expressions of ER>, PR, and Ki-67 indicating a synergic action in endometrial carcinogenesis. 28,29 On the other hand, this variability could reflect an increased genetic instability that modifies the normal receptors expression in high-risk EC. 9 Importantly, one of the major findings of the present study was the impact on survival for different patterns of immunophenotypical features.…”

Section: Discussionmentioning

confidence: 99%

Impact of Hormone Receptor Status and Ki-67 Expression on Disease-Free Survival in Patients Affected by High-risk Endometrial Cancer

Donato

Iacobelli²,

Schiavi³

et al. 2018

Int J Gynecol Cancer

View full text Add to dashboard Cite

show abstract

“…Several prospective studies focusing on postmenopausal EC patients and healthy control women have demonstrated a notable positive correlation between circulation estradiol level and EC [ 4 , 5 ]. Estrogen receptors (ER), mediating the effect of estrogen, play a key role in differentiation and invasion of EC [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Prostaglandin receptor EP3 regulates cell proliferation and migration with impact on survival of endometrial cancer patients

et al. 2017

View full text Add to dashboard Cite

BackgroundProstaglandin E2 (PGE2) receptor 3 (EP3) regulates tumor cell proliferation, migration, and invasion in numerous cancers. The role of EP3 as a prognostic biomarker in endometrial cancer remains unclear. The primary aim of this study was to analyze the prognostic significance of EP3 expression in endometrial cancer.MethodsWe analyzed the EP3 expression of 140 endometrial carcinoma patients by immunohistochemistry. RL95-2 endometrial cancer cell line was chosen from four endometrial cancer cell lines (RL95-2, Ishikawa, HEC-1-A, and HEC-1-B) according to EP3 expression level. Treated with PGE2 and EP3 antagonist, RL95-2 cells were investigated by MTT, BrdU, and wound healing assay for functional assessment of EP3.ResultsEP3 staining differed significantly according to WHO tumor grading in both whole cohort (p = 0.01) and the subgroup of endometrioid carcinoma (p = 0.01). Patients with high EP3 expression in their respective tumors had impaired progression-free survival as well as overall survival in both cohorts above. EP3 expression in the overall cohort was identified as an independent prognostic marker for progression-free survival (HR 1.014, 95%CI 1.003-1.024, p = 0.01) when adjusted for age, stage, grading, and recurrence. Treatment with EP3 antagonists induced upregulation of estrogen receptor β and decreased activity of Ras and led to attenuated proliferation and migration of RL95-2 cells.ConclusionsEP3 seems to play a crucial role in endometrial cancer progression. In the context of limited systemic treatment options for endometrial cancer, this explorative analysis identifies EP3 as a potential target for diagnostic workup and therapy.

show abstract

Expression of ER, PR, C-erbB-2 and Ki-67 in Endometrial Carcinoma and their Relationships with the Clinicopathological Features

Cited by 24 publications

References 8 publications

Histopathological and Immunohistochemical Study of Endometrial Lesions Obtained from D&C and Hysterectomy Specimens at a Tertiary Care Hospital

Histopathological and Immunohistochemical Study of Endometrial Lesions Obtained from D&C and Hysterectomy Specimens at a Tertiary Care Hospital

Impact of Hormone Receptor Status and Ki-67 Expression on Disease-Free Survival in Patients Affected by High-risk Endometrial Cancer

Prostaglandin receptor EP3 regulates cell proliferation and migration with impact on survival of endometrial cancer patients

Contact Info

Product

Resources

About